Zhiwu Jiang

Key Laboratory Of Regenerative Biology South China Institute For Stem Cell Biology And Regenerative Medicine
Guangzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 42 publications

Multi-dimensional orchestration of binders for improved CAR-T immunotherapy.

Multi-dimensional orchestration of binders for improved CAR-T immunotherapy.

Journal: Cancer letters

Published: April 01, 2026

CART-GPT: A T Cell-Informed AI Linguistic Framework for Interpreting Neurotoxicity and Therapeutic Outcomes in CAR-T Therapy.

CART-GPT: A T Cell-Informed AI Linguistic Framework for Interpreting Neurotoxicity and Therapeutic Outcomes in CAR-T Therapy.

Journal: bioRxiv : the preprint server for biology

Published: August 20, 2025

T lymphocytes expressing the switchable chimeric Fc receptor CD64 exhibit augmented persistence and antitumor activity.

T lymphocytes expressing the switchable chimeric Fc receptor CD64 exhibit augmented persistence and antitumor activity.

Journal: Cell reports

Published: May 07, 2025

RELA Ablation Contributes to Progression of Hepatocellular Carcinoma with TP53R249S Mutation and is a Potential Therapeutic Target.

RELA Ablation Contributes to Progression of Hepatocellular Carcinoma with TP53R249S Mutation and is a Potential Therapeutic Target.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: January 07, 2025

Essentials of CAR-T Therapy and Associated Microbial Challenges in Long Run Immunotherapy.

Essentials of CAR-T Therapy and Associated Microbial Challenges in Long Run Immunotherapy.

Journal: Journal of cellular immunology

Published: June 17, 2024

Clinical drug screening reveals clofazimine potentiates the efficacy while reducing the toxicity of anti-PD-1 and CTLA-4 immunotherapy.

Clinical drug screening reveals clofazimine potentiates the efficacy while reducing the toxicity of anti-PD-1 and CTLA-4 immunotherapy.

Journal: Cancer cell

Published: June 05, 2023

BCL11B and the NuRD complex cooperatively guard T-cell fate and inhibit OPA1-mediated mitochondrial fusion in T cells.

BCL11B and the NuRD complex cooperatively guard T-cell fate and inhibit OPA1-mediated mitochondrial fusion in T cells.

Journal: The EMBO journal

Published: January 05, 2023

T lymphocytes expressing the switchable chimeric Fc receptor CD64 exhibit augmented persistence and antitumor activity.

T lymphocytes expressing the switchable chimeric Fc receptor CD64 exhibit augmented persistence and antitumor activity.

Journal: Cell reports

Published: October 03, 2022

DAP10 integration in CAR-T cells enhances the killing of heterogeneous tumors by harnessing endogenous NKG2D.

DAP10 integration in CAR-T cells enhances the killing of heterogeneous tumors by harnessing endogenous NKG2D.

Journal: Molecular therapy oncolytics

Published: April 29, 2022

Human induced-T-to-natural killer cells have potent anti-tumour activities.

Human induced-T-to-natural killer cells have potent anti-tumour activities.

Journal: Biomarker research

Published: January 28, 2022

Transforming primary human hepatocytes into hepatocellular carcinoma with genetically defined factors.

Transforming primary human hepatocytes into hepatocellular carcinoma with genetically defined factors.

Journal: EMBO reports

Published: November 04, 2021

The Chemokine Receptor CCR8 Is a Target of Chimeric Antigen T Cells for Treating T Cell Malignancies.

The Chemokine Receptor CCR8 Is a Target of Chimeric Antigen T Cells for Treating T Cell Malignancies.

Journal: Frontiers in immunology

Published: November 03, 2021

Showing 1-12 of 42

Last Updated: 09/26/2026